SCHEMBL978334

SCHEMBL978334

COc1ccc(N(N)C(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.50
CA2 P00918 5/20 0.50
PARP10 Q53GL7 2/20 0.48
PARP1 P09874 1/20 0.48
PARP2 Q9UGN5 1/20 0.48
PARP4 Q9UKK3 1/20 0.48
LDHA P00338 1/20 0.47
CES2 O00748 2/20 0.47
CES1 P23141 2/20 0.47
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ESR2 Q92731 1/20 0.46
NOX1 Q9Y5S8 1/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
KEAP1 Q14145 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22501255 0.84 CA1 (0.53) CA1CA2PARP10PARP1PARP2
SCHEMBL28904603 0.84 CA1 (0.48) CA1CA2PARP10PARP1PARP2
SCHEMBL4601283 0.83 CA1 (0.54) CA1CA2PARP10PARP1PARP2
SCHEMBL11512104 0.82 NPSR1 (0.42) PARP1NPC1TP53MAPTRAB9A
SCHEMBL16671797 0.80 KDM4E (0.59) CA1CA2PARP10PARP1PARP2
SCHEMBL7998902 0.80 ALDH1A1 (0.44) CA1CA2NPC1TP53RAB9A
SCHEMBL22251873 0.79 CA1 (0.53) CA1CA2PARP10PARP1PARP2
SCHEMBL27694598 0.79 ALDH1A1 (0.50) CA1CA2PARP10PARP1PARP2
SCHEMBL20195817 0.79 CA1 (0.44) CA1CA2PARP10PARP1PARP2
Hydrochloric Acid SCHEMBL5550609 0.79 KDM4E (0.58) CA1CA2PARP10PARP1PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440830-B2 Tetrahydro-fused pyridines as histone deacetylase inhibitors 4SC AG (DE) 2013-05-14 US disclosed
EP-2197552-B1 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2012-11-21 EP disclosed
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2011-01-27 US disclosed
CN-101959881-A The 5-O-that is used for medical use replaces 3-N-phenyl-1,3,4-oxadiazole ketone BIAL PORTELA & COMPANHIA S A 2011-01-26 CN disclosed
EP-2197552-A2 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2010-06-23 EP disclosed
WO-2009037001-A2 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC3 CA1 1993/4885CA2 3576/4885PARP10 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.